Delaying the Onset of Nearsightedness Until Treatment Study
Condition: Myopia Intervention: Drug: Atropine Ophthalmic Sponsors: Ohio State University; University of Houston; State University of New York; Pennsylvania College of Optometry; Southern California College of Optometry at Marshall B. Ketchum University; University of California, Berkeley; Stanford University; Case Western R eserve University; Illinois College of Optometry; Indiana University; New England College of Optometry; University of the Incarnate Word; Southern College of Optometry; University of Missouri, St. Louis Not yet recru...
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
Qlaris Phase 2 Study in NTG Patients
Conditions: Normal Tension Glaucoma; Low-Tension Glaucoma, Bilateral; Low-Tension Glaucoma, Unspecified Eye; Glaucoma Interventions: Drug: QLS-111 ophthalmic solution, (0.015%); Drug: QLS-111 ophthalmic solution, (0.03%); Other: QLS-111 ophthalmic vehicle solution Sponsor: Qlaris Bio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
Delaying the Onset of Nearsightedness Until Treatment Study
Condition: Myopia Intervention: Drug: Atropine Ophthalmic Sponsors: Ohio State University; University of Houston; State University of New York; Pennsylvania College of Optometry; Southern California College of Optometry at Marshall B. Ketchum University; University of California, Berkeley; Stanford University; Case Western R eserve University; Illinois College of Optometry; Indiana University; New England College of Optometry; University of the Incarnate Word; Southern College of Optometry; University of Missouri, St. Louis Not yet recru...
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
Qlaris Phase 2 Study in NTG Patients
Conditions: Normal Tension Glaucoma; Low-Tension Glaucoma, Bilateral; Low-Tension Glaucoma, Unspecified Eye; Glaucoma Interventions: Drug: QLS-111 ophthalmic solution, (0.015%); Drug: QLS-111 ophthalmic solution, (0.03%); Other: QLS-111 ophthalmic vehicle solution Sponsor: Qlaris Bio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
Delaying the Onset of Nearsightedness Until Treatment Study
Condition: Myopia Intervention: Drug: Atropine Ophthalmic Sponsors: Ohio State University; University of Houston; State University of New York; Pennsylvania College of Optometry; Southern California College of Optometry at Marshall B. Ketchum University; University of California, Berkeley; Stanford University; Case Western R eserve University; Illinois College of Optometry; Indiana University; New England College of Optometry; University of the Incarnate Word; Southern College of Optometry; University of Missouri, St. Louis Not yet recru...
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
Qlaris Phase 2 Study in NTG Patients
Conditions: Normal Tension Glaucoma; Low-Tension Glaucoma, Bilateral; Low-Tension Glaucoma, Unspecified Eye; Glaucoma Interventions: Drug: QLS-111 ophthalmic solution, (0.015%); Drug: QLS-111 ophthalmic solution, (0.03%); Other: QLS-111 ophthalmic vehicle solution Sponsor: Qlaris Bio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
Multiplexing Prism Fitting for Field Expansion of Monocular Vision
Conditions: One Eye Blindness; Blind Left Eye; Blind Right Eye Intervention: Device: Multiplexing Prism Sponsors: Massachusetts Eye and Ear Infirmary; National Eye Institute (NEI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
